Corporate Structure Update and Issue of Options

AI SummaryClose X

Solvonis Therapeutics PLC has completed corporate restructuring, including renaming subsidiaries in Ireland and incorporating new R&D subsidiaries in the UK and US. They've also commenced winding down two legacy entities and sold Graft Polymer IP Limited for a nominal £1. Additionally, the company will issue 26,636,362 new ordinary shares at £0.0033 per share to settle £78,000 in outstanding liabilities, including 13,939,393 shares to Professor David Nutt. 180,000,000 share options have been granted to the CEO at an exercise price of £0.001 per share. Non-executive directors Nicholas Nelson and Dr Renata Crome have each been granted 21 million share options at exercise prices of £0.0034 and £0.00163 respectively. Post-admission, the company's issued share capital will be 6,809,403,493 ordinary shares.

Disclaimer*

UK 100

Latest directors dealings